SynBioBeta Speaker
Ashoka Madduri
Sanofi
Head, Scientific Strategy
Ashoka Madduri is the Global Head of Scientific Strategy and Intelligence at Sanofi's mRNA Center of Excellence, where he guides strategic decision-making across various technology verticals. Previously, he co-founded and led a biotech company at Yale Ventures, and provided strategic insights to early-stage life science startups. Ashoka has extensive biotech industry experience in business development, corporate strategy, and consulting across a wide variety of therapeutic drug modalities and novel delivery technologies for diverse indications. He holds an MBA from the MIT Sloan School of Management, a Ph.D. in Bio-organic Chemistry from the University of Groningen, Netherlands, and completed a PostDoc in Immunology at Harvard Medical School.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Ashoka
This Year
•
-
AIxBIO
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” - turning on only inside diseased cells or under specific physiological conditions. Neural networks trained on RNA, protein, and cellular data are unlocking a new generation of programmable therapies with unprecedented precision, from cancer drugs that remain inert until encountering tumor signals to RNA medicines capable of adapting to dynamic biological environments. But designing intelligent molecules is only part of the challenge. As AI expands the space of possible therapeutics, the field must also confront a critical question: how do we reliably build, test, and manufacture increasingly complex biological designs? This session explores the emerging continuum from AI-designed molecules to manufacturable programmable therapeutics, examining how advances in sequence design, synthesis, delivery, and validation are translating computational insight into real-world medicines. The future of medicine isn’t static molecules - it’s intelligent, adaptive therapeutics engineered across the full stack, from algorithm to clinic.
Purchase Pass
Featuring
Georgia Lu
Magnet Ventures
Founder and Managing Partner
AI-biotech investor blending M&A instincts with founder coaching.
Ashoka Madduri
Sanofi
Head, Scientific Strategy
AI-for-mRNA strategist shaping Sanofi’s genetic-medicine bets.
Jacob Becraft
Strand
CEO & Co-founder
MIT “mRNA programming language” inventor building programmable RNA medicines. Former Ron Weiss lab, interned with Bob langer
•
-
AIxBIO
Programmable Molecules: AI and the Rise of Context-Aware Therapeutics
For the first time, AI is enabling us to imagine medicines that “think” - turning on only inside diseased cells or under specific physiological conditions. Neural networks trained on RNA, protein, and cellular data are unlocking a new generation of programmable therapies with unprecedented precision, from cancer drugs that remain inert until encountering tumor signals to RNA medicines capable of adapting to dynamic biological environments. But designing intelligent molecules is only part of the challenge. As AI expands the space of possible therapeutics, the field must also confront a critical question: how do we reliably build, test, and manufacture increasingly complex biological designs? This session explores the emerging continuum from AI-designed molecules to manufacturable programmable therapeutics, examining how advances in sequence design, synthesis, delivery, and validation are translating computational insight into real-world medicines. The future of medicine isn’t static molecules - it’s intelligent, adaptive therapeutics engineered across the full stack, from algorithm to clinic.
Purchase Pass
Featuring
Georgia Lu
Magnet Ventures
Founder and Managing Partner
AI-biotech investor blending M&A instincts with founder coaching.
Ashoka Madduri
Sanofi
Head, Scientific Strategy
AI-for-mRNA strategist shaping Sanofi’s genetic-medicine bets.
Jacob Becraft
Strand
CEO & Co-founder
MIT “mRNA programming language” inventor building programmable RNA medicines. Former Ron Weiss lab, interned with Bob langer
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
